How MSK goes broke — the big cycle.

Ray Dalio’s How Countries Go Broke: The Big Cycle makes a structural argument: when a system’s obligations outrun what it produces, it doesn’t collapse dramatically. It pulls four levers, in a recognizable order, over a predictable arc. The framework was written for sovereign balance sheets. It reads uncomfortably well against musculoskeletal care in 2026 — because all four levers are firing at once.

The four levers, and where you’ve already seen them

• 1. Austerity — ration the supply. Two-to-four-week waits for access. Care delivered in the wrong mode because the right one isn’t available. Not a policy anyone announced; just what a constrained system does.
• 2. Restructuring and defaults. Large MSK and health systems missing payments, taking write-offs, and — the quieter tell — losing the ability to invest at all. A system that cannot fund innovation has already begun restructuring, whether or not anyone files.
• 3. Wealth transfer. Capital flowing to digital-first entrants at valuations legacy delivery cannot touch, underwritten by a promise of a delivery model rather than proof of one. The dollars aren’t created; they move — out of the incumbents and toward the story.
• 4. Saturation. When margin thins, the borders get crossed: adjacent professions, expanded scope, new entrants on the same turf. Everyone rations, then everyone encroaches.

Two clocks, converging

Dalio’s framework runs a short cycle and a long one, and MSK has both maturing simultaneously. The short cycle is payment reform, measured in years, and it is visibly mid-turn. The long cycle is the arrangement itself: the employer-and-federal insurance model underneath modern healthcare is roughly 75 years old — built for a population with shorter lifespans, fewer interventions, and a fraction of today’s chronic-disease load. Systems built for one population are being asked to serve a different one. That is what a long cycle reaching maturity looks like.

The closed system — where the money actually goes

Here is the part operators most often miss, and it is the whole game: this is a closed system. New money for one part of medicine is not new money. It is somebody else’s.

The direction is no longer speculative. CMS has been moving value-based mechanics directly into fee-for-service — Advanced Primary Care Management created a monthly billable wrap for team-based primary care, and the innovation-center models (ACO REACH, and LEAD behind it) are testing capitated monthly payment to an advanced primary-care team. What CMMI tests, Congress can make permanent. The US spends roughly 4–5%* of healthcare dollars on primary care against 10–15%* in peer countries, and the stated intent is to close that gap.

Close it from where? Specialty care. And orthopedics sits in the specialty bucket. The CY2027 proposed rules put numbers on it: a specialty-level RVU reduction on the order of 7%* for orthopedic surgery, work-RVU cuts to the major joint replacements, same-day E/M with modifier 25 paid at 50%*, a G2211 complexity add-on converted to a 16%* modifier on the E/M base, and a second modifier worth 32%* reserved for clinicians delivering longitudinal care inside an ACO. Primary care gets new upside. Specialists get the bill.

The one line that goes up

Now put the companion rule next to it. While the professional fee is cut, the same agency proposes a +2.4%* update to hospital outpatient and ASC facility payment — because facility updates are tied by statute to an inflation measure and physician payment is tied to nothing at all. Then the inpatient-only list finishes disappearing by 2029 and hundreds more codes move onto the ASC covered list.

Read those two rules together and the cycle stops being abstract: pay the facility more, pay the surgeon less, and use the migration of surgery out of the hospital as the evidence for both. Every year that structure persists, the professional share of the episode shrinks automatically. The ASC facility fee is one of the only lines in orthopedic Medicare with a guaranteed positive update — which is a strange and important sentence for anyone deciding what to own.

What an operator actually does about it

You cannot argue with a cycle. You can choose your position inside it.

• Stop defending the melting line. Strategy built on protecting professional-fee revenue is a strategy with a published expiration date. The fee is not being trimmed; it is being retired on a schedule.
• Own the episode, not the procedure. The value moved into the 30-day window — readmissions, post-acute spend, the failures you now eat. That’s the 30-day window and your revision rate, and both are now line items with your name on them.
• Be on the facility side of the ledger. It is the one inflation-linked line. That is what pay-per-procedure and the ASC program are actually about.
• Instrument the outcome before you’re scored on it. Under ASM, performance decides a ±9%* swing on Part B two years later, rising further after that. The centers that already run PROs, documented post-op pathways, and real primary-care relationships get to hold risk. The rest merely bear it.

Dalio’s point about big cycles isn’t that they’re catastrophes. It’s that they’re legible — the levers are visible, the order is knowable, and the people who read them early end up on the other side owning the assets that still appreciate. In MSK, that asset is the measured episode. The reorganization is already underway; the only open question is whether you priced it.

Framework: Ray Dalio, How Countries Go Broke: The Big Cycle — applied here to musculoskeletal care; the application and any errors are ours. CY2027 figures are from CMS proposed rules (CMS-1848-P, CMS-1850-P) and may change in the final rules. Figures marked * are illustrative or program-dependent; not clinical, legal, or financial advice. MSKvalue assembles independent best-of-class products with the American Joint Replacement Registry as the outcomes backbone.